The PennZone

  • Home
  • Entertainment
  • Marketing
  • Non-profit
  • Technology
  • Construction
  • Education
  • Music
  • Health

Nattokinase Supplement for Cardiovascular and Circulatory Support
The PennZone/10270754

Trending...
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
Nattokinase Heart Health Supplement
AgeImmune's Nattokinase is one of the purest professional grade supplement on the market which is beneficial for overall heart health.

NEW YORK - PennZone -- Dr. Kanevsky, D.C. C.F.M.P. introduced a new supplement to AgeImmune's product line
earlier this May 2024.
A new addition to the family is Nattokinase supplement in a form of a vegetable capsule
each containing 2,000FU (fibrin unit) representing a unit of potency, which is equal to
100mg. Dr. Kanevsky is recommending a serving size of 2 capsules. However, if you
are in excellent heart health with no family history of blood clots, 1 capsule is enough as
a preventative measure.
Nattokinase is an enzyme derived from Japanese soybean called Natto via fermentation
process with a bacteria called Bacillus subtilis. Natto has been consumed as a
traditional food in Asia for over 2000 years and is believed to be a significant contributor

More on The PennZone
  • Colonial Nissan Helps Multiple Generations of the Community Find Their Next Vehicle
  • ImagineX Acquires Payteros to Strengthen Digital Transformation Capabilities
  • From Pizza to Playlists: Marty The Pizza Guy Delivers Three Delicious New Songs
  • CAPO Supply Launches New Website Serving Western Pennsylvania and Eastern Ohio
  • Meals on Wheels of the Greater Lehigh Valley Receives $15,000 PPL Foundation Grant to Expand Access

to the longevity of the Japanese people. Although natto has been consumed in Asia for
thousands of years, the fibrinolytic and antithrombolytic property of Nattokinasae was
only discovered in 1987. Recent studies demonstrated that high natto intake is
associated with decreased risk of cardiovascular disease.
This was a sufficient reason for Dr. Kanevsky to add Nattokinase to his line of products.
There is some early evidence that nattokinase may thin the blood and help break up
blood clots. This might protect against heart disease and conditions caused by blood
clots such as stroke, heart attack, and others.
Other studies show that nattokinase may help lower blood pressure and reduce
inflammation in the body.
Unlike traditional blood thinning medications, nattokinase is a natural, widely available
and inexpensive supplement with minimal to no side effects which makes is very

More on The PennZone
  • Salestrics Introduces PraiseEngine: The AI-Native Review Engine Built to Fix Social Proof
  • BTAQ Unveils Easier Photo Upload Capabilities
  • K2 Integrity Names Michael Kallabat Global Head of Investigations and Disputes
  • WebDrafter Highlights How AI Search Is Reshaping Online Visibility
  • Socialhose Eyes Southeast Asia and Rejects the Copy-Paste Expansion Playbook

attractive to Dr. Kanevsky's patients searching for an all-natural approach to their
health.
Having a large database of functional medicine patients Dr Kanevsky easily analyzed
the frequency of complains of a poor heart health, circulation, blood pressure and came
to a conclusion that Nattokinase will become one of the most popular products for
AgeImmune.
As always encapsulated without harmful excipients such as magnesium stearate, silicon
dioxide or titanium dioxide, AgeImmune's Nattokinase is one of the purest professional
grade supplement on the market.
Nattokinase supplement is derived from soy. Dr. Kanevsky warns that if you are allergic
to soy, you shouldn't be taking Nattokinase. It is currently available for purchase at a
discounted price of 21.99 on AgeImmune's website and on Amazon

Contact
AgeImmine
***@netembark.com


Source: Nattokinase Heart Health Supplement

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!
  • Harrisburg's newest restaurant, Eleve, sells out entire inventory during Grand Opening
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • What's New in Hokkaido, Autumn 2026
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year
  • Elevate Your Sneakers With Crep Protect Trek Laces
  • Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • SKRAP Finds Hope Through Heartache on Powerful New Single "Shellshock"
  • CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Valgar LLC Launches The Briefing Room: Education Leaders
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
  • New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000

Popular on PennZone

  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Community Partnership Brings Live Theater to 150+ Young People
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration

Similar on PennZone

  • FDA Food Recall Notices After Outbreak Linked to 98 Hospitalizations: Practical Tips for Safer Grocery Shopping
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • MedSocially Expands Access to Healthcare Networking Platform
  • Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us